Biosite pushes on with sepsis test:
This article was originally published in Clinica
Executive Summary
Biosite is developing a three-biomarker point-of-care test that could help assess sepsis progression. Following the release of preliminary study data for the test, the firm claimed that it is "on track to launch a prospective multicentre clinical study in the second quarter of 2007." The study will form the basis of an US FDA submission, said the San Diego, California company. The test, called the Triage sepsis panel, consists of biomarkers neutrophil gelatinase-associated lipocalcin (NGAL), c-reactive protein (CRP) and macrophage inflammatory protein-3 (MIP-3).